

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

C Number:

C11054-01

Study Gender:

Both

PWG Approval Date

See web page for date of PWG Approval

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

	Male						
	Treatment Groups (mg/kg)						
	0	1	10	30	100	300	800
Disposition Summary							
Animals Initially In Study	13	10	10	13	13	13	10
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 28 - 29)	13	10	10	13	13	13	10
Animals Examined Microscopically	10	10	10	10	10	10	10
ALIMENTARY SYSTEM							
ESOPHAGUS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(1)	(0)	(0)	(10)
EXTRAMEDULLARY HEMATOPOEISIS	2 [1.0]						
HEPATODIAPHRAGMATIC NODULE	1			1			
PANCREAS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
CARDIOVASCULAR SYSTEM							
AORTA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INFLAMMATION; CHRONIC	2 [1.0]						

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

Test Compound: Sulfolane

CAS Number: 126-33-0

Male

Treatment Groups (mg/kg)

	0	1	10	30	100	300	800
ENDOCRINE SYSTEM							
ADRENAL GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(8)
HYPERPLASIA; DIFFUSE							1 [1.0]
PITUITARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
THYROID GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
EPIDIDYMIS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
PREPUTIAL GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INFLAMMATION; CHRONIC-ACTIVE	1 [1.0]						3 [1.0]
PROSTATE GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SEMINAL VESICLE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
TESTIS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HEMATOPOIETIC SYSTEM							
BONE MARROW	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(10)	(10)	(10)	(10)	(10)	(10)
THYMUS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM							
MAMMARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SKIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPHOID SYSTEM							
No Tissues/Organs Examined							

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

	Male						
	Treatment Groups (mg/kg)						
	0	1	10	30	100	300	800
MUSCULOSKELETAL SYSTEM							
BONE, FEMUR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM							
BRAIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)
EDEMA; INTRAMYELINIC	1 [1.0]						
RESPIRATORY SYSTEM							
LUNGS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INFILTRATION, CELLULAR; HISTIOCYTE	5 [1.0]						1 [1.0]
NOSE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY EPITHELIUM; GOBLET CELL; HYPERPLASIA							1 [2.0]
NASOLACRIMAL DUCT; INFLAMMATION; SUBACUTE							1 [1.0]
RESPIRATORY EPITHELIUM; INFLAMMATION; CHRONIC	2 [1.0]						1 [1.0]
RESPIRATORY EPITHELIUM; INFLAMMATION; SUBACUTE	2 [1.0]						1 [1.0]
TRANSITIONAL EPITHELIUM; INFLAMMATION; CHRONIC	1 [1.0]						1 [1.0]
TRANSITIONAL EPITHELIUM; INFLAMMATION; SUBACUTE	2 [1.0]						1 [1.0]
TRACHEA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM							
EYE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
RETINA; DYSPLASIA	1						
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HYPERPLASIA	1 [1.0]						

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

	Male						
	Treatment Groups (mg/kg)						
	0	1	10	30	100	300	800
URINARY SYSTEM							
KIDNEY	(10)	(10)	(10)	(10)	(10)	(10)	(10)
RENAL TUBULE; ACCUMULATION; HYALINE DROPLET		6 [1.0]	8 [1.0]	10 [1.1]	9 [1.1]	10 [2.6]	10 [3.1]
RENAL TUBULE; HYPERPLASIA; ATYPICAL	1 [1.0]						
NEPHROPATHY; CHRONIC-PROGRESSIVE	8 [1.0]	7 [1.0]	9 [1.0]	9 [1.1]	9 [1.0]	9 [1.1]	10 [1.0]
URINARY BLADDER	(10)	(0)	(0)	(0)	(0)	(0)	(10)

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

Test Compound: Sulfolane

CAS Number: 126-33-0

Female**Treatment Groups (mg/kg)**

	0	1	10	30	100	300	800
--	---	---	----	----	-----	-----	-----

Disposition Summary

Animals Initially In Study	13	10	10	13	13	13	10
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 28 - 29)	13	10	10	13	13	13	10

Animals Examined Microscopically**ALIMENTARY SYSTEM**

ESOPHAGUS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, CECUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, COLON	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, LARGE, RECTUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
FOREIGN BODY							1
INFLAMMATION; ACUTE							1 [2.0]
INTESTINE, SMALL, DUODENUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, ILEUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INTESTINE, SMALL, JEJUNUM	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LIVER	(10)	(0)	(0)	(0)	(0)	(1)	(10)
EXTRAMEDULLARY HEMATOPOEISIS	3 [1.0]						3 [1.0]
FATTY CHANGE; FOCAL	2 [1.0]						
HEPATODIAPHRAGMATIC NODULE						1	
MINERAL							1 [2.0]
PANCREAS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SALIVARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
STOMACH, FORESTOMACH	(10)	(0)	(0)	(0)	(0)	(0)	(10)
STOMACH, GLANDULAR	(10)	(0)	(0)	(0)	(0)	(0)	(10)

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

Female							
	Treatment Groups (mg/kg)						
	0	1	10	30	100	300	800
CARDIOVASCULAR SYSTEM							
AORTA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HEART	(10)	(0)	(0)	(0)	(0)	(0)	(10)
CARDIOMYOPATHY							2 [1.0]
ENDOCRINE SYSTEM							
ADRENAL GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(9)
PITUITARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
PARS DISTALIS; CYST	1						
RATHKES CLEFT; DILATION							2
THYROID GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
CERVIX	(10)	(0)	(0)	(0)	(0)	(0)	(10)
CLITORAL GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INFLAMMATION; CHRONIC-ACTIVE	2 [1.0]						1 [2.0]
OVARY	(10)	(0)	(0)	(0)	(0)	(0)	(10)
UTERUS	(10)	(0)	(0)	(1)	(0)	(0)	(10)
ANGiectasis							1 [1.0]
CYST				1			
VAGINA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HEMATOPOIETIC SYSTEM							
BONE MARROW	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPH NODE, MANDIBULAR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPH NODE, MESENTERIC	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SPLEEN	(10)	(10)	(10)	(10)	(10)	(10)	(10)
THYMUS	(10)	(0)	(0)	(0)	(0)	(0)	(10)

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

Female

Treatment Groups (mg/kg)

	0	1	10	30	100	300	800
INTEGUMENTARY SYSTEM							
MAMMARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SKIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)
LYMPHOID SYSTEM							
No Tissues/Organs Examined							
MUSCULOSKELETAL SYSTEM							
BONE, FEMUR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM							
BRAIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM							
LUNGS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
INFILTRATION, CELLULAR; HISTIOCYTE	2 [1.0]						
METAPLASIA; OSSEOUS	2						
NOSE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY EPITHELIUM; INFLAMMATION; CHRONIC	1 [2.0]						
RESPIRATORY EPITHELIUM; INFLAMMATION; SUBACUTE	4 [1.5]						2 [1.0]
TRANSITIONAL EPITHELIUM; INFLAMMATION; SUBACUTE	3 [1.0]						3 [1.0]
TRACHEA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM							
EYE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
HARDERIAN GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
URINARY SYSTEM							
KIDNEY	(10)	(0)	(0)	(0)	(0)	(0)	(10)
NEPHROPATHY; CHRONIC-PROGRESSIVE	5 [1.0]						8 [1.0]
URINARY BLADDER	(10)	(0)	(0)	(0)	(0)	(0)	(10)

INTEGUMENTARY SYSTEM

MAMMARY GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
SKIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)

LYMPHOID SYSTEM

No Tissues/Organs Examined

MUSCULOSKELETAL SYSTEM

BONE, FEMUR	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-------------	------	-----	-----	-----	-----	-----	------

NERVOUS SYSTEM

BRAIN	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-------	------	-----	-----	-----	-----	-----	------

RESPIRATORY SYSTEM

LUNGS	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-------	------	-----	-----	-----	-----	-----	------

INFILTRATION, CELLULAR; HISTIOCYTE

INFILTRATION, CELLULAR; HISTIOCYTE	2 [1.0]						
------------------------------------	---------	--	--	--	--	--	--

2 [1.0]

METAPLASIA; OSSEOUS	2						
---------------------	---	--	--	--	--	--	--

NOSE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
------	------	-----	-----	-----	-----	-----	------

RESPIRATORY EPITHELIUM;

INFLAMMATION; CHRONIC

RESPIRATORY EPITHELIUM; INFLAMMATION; CHRONIC	1 [2.0]						
--	---------	--	--	--	--	--	--

1 [2.0]

RESPIRATORY EPITHELIUM; INFLAMMATION; SUBACUTE	4 [1.5]						2 [1.0]
---	---------	--	--	--	--	--	---------

RESPIRATORY EPITHELIUM; INFLAMMATION; SUBACUTE	4 [1.5]						2 [1.0]
---	---------	--	--	--	--	--	---------

TRANSITIONAL EPITHELIUM; INFLAMMATION; SUBACUTE	3 [1.0]						3 [1.0]
--	---------	--	--	--	--	--	---------

TRACHEA	(10)	(0)	(0)	(0)	(0)	(0)	(10)
---------	------	-----	-----	-----	-----	-----	------

SPECIAL SENSES SYSTEM

EYE	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-----	------	-----	-----	-----	-----	-----	------

HARDERIAN GLAND	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-----------------	------	-----	-----	-----	-----	-----	------

URINARY SYSTEM

KIDNEY	(10)	(0)	(0)	(0)	(0)	(0)	(10)
--------	------	-----	-----	-----	-----	-----	------

NEPHROPATHY; CHRONIC-PROGRESSIVE

NEPHROPATHY; CHRONIC-PROGRESSIVE	5 [1.0]						8 [1.0]
----------------------------------	---------	--	--	--	--	--	---------

5 [1.0]

URINARY BLADDER	(10)	(0)	(0)	(0)	(0)	(0)	(10)
-----------------	------	-----	-----	-----	-----	-----	------

Study Number: C11054-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA18: Incidence Rates of Non-Neoplastic Lesions by Anatomic Site [a] with Average Severity Grades [b]

Test Compound: Sulfolane

CAS Number: 126-33-0

Date Report Requested: 11/13/2018

Time Report Requested: 13:58:19

Lab: Battelle

LEGEND

[a] Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

[b] Mean severity grade denoted by 1 - minimal, 2 - mild, 3 - moderate, 4 - marked

Number of animals with observation reported with mean severity grade in square brackets

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day

** END OF REPORT **